Common questions about Apremilast (FAQ)
Q: What is the main reason Apremilast is prescribed?
Regulatory documents state that Apremilast is a prescription medicine indicated for several specific chronic inflammatory conditions. It is used to treat active psoriatic arthritis, moderate to severe plaque psoriasis in adults and eligible children who require systemic therapy, and oral ulcers associated with Behçet’s disease in adults.
Q: Does Apremilast work right away, or does it take time?
Apremilast does not typically work immediately. Studies reviewed by regulatory bodies show that the key assessment period for improvements to be up to 24 weeks of treatment. In studies, if no evidence of therapeutic benefit is shown after 24 weeks, the continuation of treatment may be discussed.
Q: Are there any special blood tests needed while taking Apremilast?
The drug's safety profile does not necessitate routine laboratory monitoring such as regular blood tests. Regulatory documents do, however, recommend that patient weight is regularly monitored during treatment.
Q: What should I do if my side effects don't go away after the first few weeks?
The most common side effects, especially gastrointestinal symptoms like diarrhea and nausea, tend to occur during the initial weeks of therapy. Official guidance on managing severe gastrointestinal symptoms indicates that they may be addressed by a dose reduction or suspension of the medication. If severe or persistent side effects occur, communication with the prescriber is necessary.
Q: Can Apremilast be used by people with liver problems?
Yes, regulatory documents indicate that Apremilast can generally be used by people with liver issues. The official labeling states that no dosage adjustment is required for patients who have any degree of hepatic (liver) impairment.
Q: What is the purpose of the starting dose pack for Apremilast?
Official prescribing information describes a mandatory initial gradual dosage schedule. The gradual schedule is designed to address the potential for gastrointestinal symptoms that are commonly experienced when initiating the therapy, consistent with official guidance.
Q: Do I need to avoid certain vaccines while on Apremilast?
Regulatory documents do not mention specific restrictions on vaccines (such as live vaccines) for individuals taking Apremilast. Official information describes the drug as an immunomodulatory agent, and it is classified differently from traditional immunosuppressants.
Q: If Apremilast is working, how will I know?
Clinical trials measure effectiveness based on standardized criteria, such as a drop in the Psoriasis Area and Severity Index (PASI) score for skin conditions or a reduction in joint symptom severity for arthritis. Any clinical response or lack thereof is monitored during regular clinical response evaluations performed by a healthcare provider.
Q: Is Apremilast a corticosteroid?
No. Apremilast belongs to the pharmacological class known as a Phosphodiesterase 4 (PDE4) inhibitor. This means it works through a targeted mechanism at the cellular level to reduce inflammation, which is distinct from how corticosteroids function.
Q: Are there official research studies on Apremilast for types of arthritis other than psoriatic arthritis?
According to official regulatory indications, Apremilast is approved for active psoriatic arthritis. Other types of arthritis, such as rheumatoid arthritis or gout, are not listed among the officially approved uses for the medication.
Q: Is Apremilast available in a generic version?
Yes. While the drug was initially only available under its brand name, the U.S. Food and Drug Administration (FDA) has since approved the first generic version of Apremilast tablets.
Q: Are there special warnings about using Apremilast if I have certain infections?
Upper respiratory tract infection and nasopharyngitis are listed as common side effects, but official labeling does not carry a standard warning or precaution regarding a broad risk of serious infections that are typically associated with traditional immunosuppressant drugs.
Q: Is Apremilast used for severe cases or milder cases?
Apremilast is indicated for moderate to severe plaque psoriasis in adults and eligible children who need systemic therapy, and for active psoriatic arthritis. This places its approved use in cases where the condition is not considered mild.
Q: What happens if I accidentally take too much Apremilast?
In the event of an accidental overdose, a medical professional must be contacted immediately. Management of an overdose should consist of symptomatic and supportive care, provided by a medical professional.
Q: What is the difference between the uses of Apremilast in psoriasis versus psoriatic arthritis?
Apremilast is indicated for two separate conditions: plaque psoriasis (a skin condition) and active psoriatic arthritis (a joint condition). Efficacy is measured by different clinical outcomes for each use, focusing on skin clearance for psoriasis and joint symptoms for psoriatic arthritis.
Q: How is Apremilast different from other common treatments for psoriasis?
Apremilast belongs to the pharmacological class known as PDE4 inhibitors. It is an oral systemic therapy, meaning it works throughout the body by targeting a specific enzyme. This is a key difference when compared to topical treatments, which are applied only to the skin, and injectable biologic therapies.
Q: Is Apremilast safe to use long-term?
Regulatory information includes data from large analyses that have studied exposure to Apremilast for periods of up to five years. It is also noted that the long-term effects beyond five years are not fully established through continuous, blinded studies.
Q: What is the difference between Apremilast and a traditional immunosuppressant?
Apremilast is officially described as an immunomodulatory agent and a selective PDE4 inhibitor. Its mechanism of action works to balance inflammatory signals. This distinguishes it from traditional immunosuppressants, which act on the immune system in different ways.
Q: Does Apremilast suppress the immune system in a major way?
Official information describes the drug’s action as modulating pathways associated with inflammatory signaling by dampening the inflammatory cascade. This differs from the broad immune system effects associated with traditional immunosuppressants.
Q: Why do some patients stop taking Apremilast?
Official reports show that some patients discontinue treatment, often due to adverse reactions. Severe gastrointestinal events (like persistent diarrhea or nausea) and cases of unexplained or clinically significant weight loss are documented reasons that may lead to the suspension or discontinuation of the medication.
Q: Can Apremilast cause diarrhea, and if so, how is it managed?
Diarrhea is listed in regulatory documents as a Very Common side effect, especially when first starting treatment. In clinical practice, the management of severe gastrointestinal symptoms may involve the temporary suspension of the drug or a dose reduction, as determined by the prescriber.
Q: What is the general expectation for how quickly skin symptoms might improve?
Clinical trial results used to support the approval of the drug in plaque psoriasis typically focused on primary assessment points at the 16-week mark. This timeframe reflects the period over which significant measurable changes in skin symptoms are evaluated in studies.
Q: What is the general expectation for how quickly joint symptoms might improve?
For active psoriatic arthritis, key clinical trials focused on primary assessment points between 16 and 24 weeks. This is the general timeframe used in official studies to evaluate and measure changes in physical function scores and joint symptoms.
Q: Why is the drug intended to be taken twice a day?
The twice-daily (BID) schedule is the standard maintenance dose defined in official prescribing information. This frequency is based on the drug’s pharmacological profile to maintain steady and effective levels of the medicine in the body between doses.
Q: Has Apremilast been shown to interact with common over-the-counter supplements?
Official interaction guidance specifically states that the herbal product St. John's Wort is not recommended because it can significantly decrease the effectiveness of Apremilast. Information on interactions with other common vitamins or non-herbal supplements is not detailed in the core regulatory documents.
